MCM
CYCN icon

MAI Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

MAI Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155 Hold
100
– – ﹤0.01% 4670
2025
Q4 		$127 Hold
100
– – ﹤0.01% 4127
2025
Q3 		$230 Hold
100
– – ﹤0.01% 3697
2025
Q2 		$291 Hold
100
– – ﹤0.01% 3831
2025
Q1 		$250 Hold
100
– – ﹤0.01% 3298
2024
Q4 		$322 Buy
+100
New +$278 ﹤0.01% 3335

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

MAI Capital Management's CYCN Position: Q1 2026 in Review

MAI Capital Management held its Cyclerion Therapeutics (CYCN) position steady in Q1 2026 at 100 shares worth $155. The position accounts for ﹤0.01% of the portfolio, ranked #4670.

MAI Capital Management first reported a position in CYCN in Q4 2024 and has held it in 6 quarters since. The position peaked at $322 in Q4 2024. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • MAI Capital Management held 100 shares of Cyclerion Therapeutics worth $155 as of Q1 2026.
  • MAI Capital Management left its Cyclerion Therapeutics share count unchanged in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4670 holding.
  • MAI Capital Management first reported a position in Cyclerion Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Cyclerion Therapeutics position peaked at $322 in Q4 2024.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.